ArticleACS omega2026
Glycosylation Matters: Network Pharmacology-Based and Molecular Docking Analysis of Resveratrol Glycosylated Derivatives on Parkinson's Disease.
Article in ACS omega, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Resveratrol (RV), a natural polyphenol, has been extensively studied for its neuroprotective potential in Parkinson's Disease (PD), but its clinical translation is limited by poor bioavailability and rapid metabolism. Glycosylated derivatives, including polydatin and resveratrol-3-α-glucoside, have been proposed to improve the solubility and stability. This study compared the pharmacokinetic properties of RV and its derivatives and examined their molecular interactions with PD-related targets. ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity) analysis showed that, despite improved solubility, RV retained a more favorable overall pharmacokinetic profile. Target prediction combined with Gene Ontology (GO) enrichment, Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway analysis, and protein-protein interaction (PPI) network construction identified 50 potential targets, with 11 prioritized for molecular docking. Glycosylated derivatives exhibited binding affinities for all targets stronger than those of RV, with TNF-α, PPARγ, and ERBB2 highlighted as key candidates. These findings indicate that RV glycosylation may enhance therapeutic potential for PD treatment by promoting stronger molecular interactions with critical targets, though
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.